The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Salvatore Grisanti et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationDavid Miles, Hamdy Abdel Azeem, Eva Ciruelos et al.|Annals of Oncology|2021Cited by 92
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design SimulationLorenzo Gerratana, Massimo Cristofanilli, Jean‐Yves Pierga et al.|The Oncologist|2022Cited by 13
The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “<i>indolent</i>” stage IV disease (Stage IV<sub>indolent</sub>).Andrew A. Davis, Massimo Cristofanilli, Jean‐Yves Pierga et al.|Journal of Clinical Oncology|2018Cited by 5
An improved method for the diagnostic approach of <i>α</i><sup>+</sup>‐thalassaemiaZoe Repapinou, A. Loutradi-Anagnostou, PH. KARABABA et al.|International Journal of Laboratory Hematology|2006Cited by 0